Invex Therapeutics Ltd Overview
Invex Therapeutics is a Perth-based, ASX-listed micro-cap biopharmaceutical company built around the repurposing of Exenatide — an already-approved GLP-1 receptor agonist — to treat neurological disorders associated with raised intracranial pressure (ICP). Its sustained-release formulation, trademarked Presendin™, reached a registration-directed Phase III trial in idiopathic intracranial hypertension (IIH EVOLVE) before the Board terminated the study in August 2023, concluding that the rise of cheaper, more weight-reducing GLP-1 drugs such as semaglutide would make an orphan-priced Presendin uneconomic in IIH. The company subsequently returned A$14.0m to shareholders, dismantled its UK clinical operation, and reverted to a preclinical, virtual model. Its residual value now rests on (i) patents and orphan drug designations covering GLP-1RAs for raised ICP, (ii) preclinical Alzheimer's disease data generated with Tessara Therapeutics, and (iii) a clean, debt-free balance sheet with roughly A$4m of cash that positions it as a potential vehicle for an asset acquisition or reverse transaction.
Company's own description (FY2026 Annual Report, Directors' Report)
The FY2026 Annual Report describes Invex as a biopharmaceutical group focused on repurposing an approved drug, Exenatide, for the treatment of neurological conditions derived from or involving raised intracranial pressure. It identifies the principal activity during FY2026 as the development of Exenatide, including the generation of new preclinical data in Alzheimer's disease (AD) under a collaboration with Tessara Therapeutics, and notes that the Board held discussions with several third parties owning complementary assets that could create additional value for shareholders. The FY2024 report extended the stated scope to traumatic brain injury (TBI), stroke and hydrocephalus, and to early-stage data in glaucoma (via lowering of intraocular pressure).
Independent characterisation
In practice, Invex today is best characterised as a cash-backed, intellectual-property holding company with a low-cost preclinical research option. It has:
- No revenue-generating products, services, subscriptions or licences. All income since listing has been "other income" — interest on cash deposits and R&D tax incentive rebates (Australian and UK).
No clinical-stage program: The only clinical asset (Presendin in IIH) was terminated in FY2024; the related manufacturing relationship with Peptron, Inc. was mutually terminated on 22 December 2023, with Peptron receiving an exclusive royalty-free licence to commercialise Presendin for IIH in Korea and China and a first right of refusal over global IIH development rights.
A virtual operating model: Research is conducted by contract research partner Tessara Therapeutics (ADBrain™ human 3D neural microtissue model). Administration is outsourced to company secretarial/accounting providers.
A stated corporate-development mandate: Since FY2024 the Board has repeatedly said it is assessing complementary neurological assets and, per a BIO International Convention partnering profile, has also been seeking partners to acquire its core raised-ICP IP for cash, equity or a combination.
Business model and revenue model
| Dimension | Assessment |
|---|---|
| Business model | Drug repurposing / specialty biotech; historically "develop to Phase III then partner or commercialise" in an orphan indication; now preclinical research plus corporate development |
| Revenue mix (product / service / subscription / licensing) | 0% / 0% / 0% / 0%. No operating revenue in any year FY2022–FY2026 |
| Other income sources | Interest income; R&D tax incentive rebates (Australia; UK until FY2025); minor "other revenue" (A$16,917 in FY2026) |
| Value chain position | Early-stage R&D and IP owner; no manufacturing, distribution or sales capability. Drug substance previously sourced from Peptron (Korea) |
| Intended customers (if commercialised) | Neurologists, neuro-ophthalmologists and neurosurgical/ICU teams treating raised-ICP conditions; payers and health systems in EU/UK/US/Australia |
| End-markets targeted | IIH (orphan), moderate-to-severe TBI (orphan in EU), hydrocephalus/NPH and meningitis (patent claims), glaucoma (early data), Alzheimer's disease (preclinical) |
Strategy
Stated strategy themes (FY2024–FY2026 Annual Reports and quarterlies)
-
Generate new preclinical data for Exenatide in CNS indications, presently Alzheimer's disease, to build an evidence base for partnering — the FY2026 report states that the expanded Tessara program is intended to strengthen understanding of Exenatide's mechanistic profile and support engagement with prospective development and commercialisation partners.
-
Maintain and extend IP and regulatory designations (renewed EU TBI ODD in FY2026; patents in US/EU).
-
Pursue complementary neurological assets via acquisition or in-licensing, preferably in neuroscience or orphan disease (discussions with "a number of potential third parties" referenced in FY2026).
-
Divest core raised-ICP GLP-1RA IP for cash, equity or both (BIO partnering profile; roic.ai summary of 2025 disclosures).
-
Cost discipline — minimal overhead, outsourced administration, no employees.
Strategic initiatives in the last 24 months (Oct 2024 – Oct 2026)
| Initiative | Date | Description | Status |
|---|---|---|---|
| Tessara collaboration (phase 1) | 15 Aug 2024 | Exenatide tested in ADBrain™ AD model; showed improved neuronal survival | Completed |
| Tessara collaboration expansion | Mar 2025 | Neuroinflammation, glucose metabolism, neural network and AD biomarker analyses | Results reported in FY2026 (Nf-L −40%, IL-6/IL-8 reductions) |
| Acquisition of rare neurological disease company (Fragile X focus) | Exclusive negotiations to 29 Sep 2025 | Would have diversified pipeline into rare neurodevelopmental disorders | Terminated 30 Sep 2025 |
| EU TBI orphan designation renewal | H1 FY2026 | Maintains EU orphan pathway | Completed |
| UK subsidiary wind-up | Feb 2026 | Simplified structure | Completed |
| Expanded Tessara program | 24 Apr 2026 | Head-to-head Exenatide vs dulaglutide; combinations with approved AD symptomatic drugs; combinations with naturally occurring synergistic factors; cytotoxicity, viability and ferroptosis assays | In progress (A$379k R&D outflow in Q4 FY2026) |
| Treasury: term deposits | FY2026 | A$2.5m placed on term deposit | Ongoing |
ESG commitments, cost programs and guidance
No sustainability or ESG commitments have been announced. No formal cost-reduction program with numeric targets has been published, though overhead reduction is evident. Management has issued no financial guidance or medium-term targets. The FY2026 Directors' Report states there are no likely developments not already disclosed.
Products & Services
Invex has no marketed products or services. Its "portfolio" consists of one molecule (Exenatide) across several indications, plus IP and regulatory designations.
Presendin™ (sustained-release Exenatide) — lead asset
| Attribute | Detail |
|---|---|
| Description | Once-weekly, subcutaneous, sustained-release Exenatide microsphere formulation originally developed by Peptron, Inc. (KOSDAQ: 087010); Presendin™ is Invex's granted trademark |
| Mechanism | GLP-1 receptor agonism; preclinical work by Prof Sinclair identified GLP-1RAs as reducing cerebrospinal fluid secretion and brain pressure |
| Development status | IIH: Phase III terminated (Aug 2023). Other indications: preclinical |
| Target customer | Neurology/neuro-ophthalmology (IIH), neurocritical care (TBI) |
| Launch year | Not launched |
| Pricing model | Not applicable; the company's own analysis concluded orphan-premium pricing was not achievable given GLP-1RA price points |
| Out-licence | Exclusive royalty-free licence to Peptron for IIH in Korea and China (Dec 2023); Peptron holds a first right of refusal over global IIH development rights |
Indication-by-indication catalog
| Program | Stage | Key data / status | Regulatory/IP support |
|---|---|---|---|
| Idiopathic Intracranial Hypertension (IIH) | Phase III terminated (IIH EVOLVE, NCT05347147) | Phase II "IIH Pressure" trial (reported May 2020; published in Brain) showed ICP reduction; Phase III enrolled 13 patients before closure | EMA and FDA orphan drug designations (IIH); paediatric investigation plan approved by EMA PDCO |
| Moderate-to-severe Traumatic Brain Injury (TBI) | Preclinical | No clinical data; proof-of-concept trial was "under consideration" in FY2023 but never initiated | EMA ODD granted 23 Jun 2023 and renewed in FY2026; US ODD filed late FY2023 — grant status not publicly disclosed; US Patent 11,738,067 includes brain injury/trauma claims |
| Hydrocephalus / normal pressure hydrocephalus / meningitis | Preclinical (IP-led) | No disclosed clinical data | EP4000630 (Decision to Grant, 22 Nov 2023) |
| Acute stroke | Preclinical / conceptual | Named in early prospectus-era descriptions; no disclosed program activity since FY2024 | Covered by raised-ICP patent family |
| Glaucoma | Early preclinical | Early-stage data on lowering intraocular pressure referenced in FY2024 report; no further updates | — |
| Alzheimer's disease (AD) | Preclinical (in vitro, human 3D microtissue) | In Tessara ADBrain™: ~40% reduction in secreted neurofilament light chain; reductions in IL-6 and IL-8; possible effect on amyloid-beta (confounded by GAPDH change); no effect on phosphorylated Tau or insulin-dependent glucose uptake | Potential new IP flagged in 2025; no grant disclosed |
Flagship "offering" summary
The only named flagship is Presendin™. There are no product versions, pricing schedules or commercial SKUs.
Financial Narrative
All tables: AUD thousands unless noted; FY = year ended 30 June. Sources: FY2023 Annual Report (FY2022–FY2023 data), FY2024 Annual Report (FY2024), FY2026 Annual Report (FY2025–FY2026). Figures rounded to nearest A$1,000.
Income statement
Notes and definitions. EBITDA is computed as pre-tax loss less interest income; the group has no depreciation, amortisation or interest expense. Gross, operating, EBITDA and net margins are not meaningful because operating revenue is nil in every year; revenue CAGR is likewise not meaningful. The FY2026 Appendix 4E reports "Net Tangible asset per share" of 1.80 cents for FY2026 and 0.63 cents for FY2025 — these figures equal the loss per share and appear to be a labelling error; computed NTA per share is approximately 5.20 cents (FY2026) and 6.98 cents (FY2025). The FY2023 4E similarly shows NTA of 0.28/0.38, inconsistent with the balance sheet. A minor discrepancy also exists in the FY2026 tax note, which cites a pre-tax loss of A$1,332,352 versus A$1,352,352 in the income statement.
Commentary. The P&L trajectory maps directly to the clinical program lifecycle. FY2023 was peak spend (A$7.40m R&D) as IIH EVOLVE commenced, with Phase III trial costs of A$3.85m and drug manufacturing of A$0.74m. FY2024 R&D fell 72% to A$2.04m as the trial was wound down, and the net loss fell 79% to A$1.64m, cushioned by a A$1.21m UK R&D rebate. FY2025 was the cost trough: net loss of only A$0.48m, with R&D of A$0.20m and admin of A$0.72m. FY2026 marks an inflection back upward — net loss rose 184% to A$1.35m, driven by (i) Tessara-related consultant costs (R&D consultants A$0.44m vs A$0.14m) and (ii) a governance contest: legal fees jumped to A$0.21m (FY2025: A$4k), audit/corporate advice/tax fees doubled to A$0.14m, NED fees more than doubled to A$0.13m, and A$75k of transaction costs were incurred on the aborted acquisition. Simultaneously, interest income fell 45% as cash declined and the R&D rebate stream largely ended with the UK subsidiary's closure.
R&D expense detail
FY2026 Phase III trial cost was A$443 (rounds to zero).
Administration expense detail
FY2025 admin also included A$38k of UK director fees (FY2026: A$3k).
Balance sheet
Commentary. The balance sheet is entirely current: no PP&E, no capitalised development, no intangibles (all R&D is expensed per policy), no leases and no debt. Equity fell 86% between FY2022 and FY2026, of which A$14.0m was the FY2024 capital return and the remainder cumulative losses. The FY2026 shift of A$2.5m into term deposits (A$500k of cash also on fixed term) is a treasury decision, not a change in liquidity. Unrecognised deferred tax assets of A$2.82m at FY2026 (Australian tax losses A$2.74m tax-effected) represent an under-appreciated asset for a potential acquirer or reverse-takeover vehicle, subject to continuity-of-ownership/business tests. Foreign tax losses (A$1.13m tax-effected at FY2024) were effectively lost with the UK subsidiary's dissolution.
Cash flow
Quarterly granularity, FY2026 (Appendix 4C): Q3 FY2026 operating outflow approximately A$79k (R&D A$53k; admin A$67k vs A$444k in Q2 FY2026, the Q2 spike reflecting s249D meeting costs and termination payments to departing directors and the company secretary); Q4 FY2026 operating outflow A$501k (R&D A$379k for the expanded Tessara program; admin A$135k; related-party payments A$54k). Cash and equivalents per Q3 4C: A$4.517m; per Q4 4C: A$4.016m.
Runway: At the FY2026 operating burn of A$1.36m, cash and deposits of A$4.02m represent roughly 3.0 years of funding; at the Q4 FY2026 quarterly rate of A$0.50m, roughly 8 quarters. A transaction or expanded program would shorten this materially.
Ratios
ROE and ROA match Market Index's published FY2024 (-28.86%, -26.83%) and FY2025 (-9.09%, -8.72%) figures. ROIC, net debt/EBITDA, interest coverage, asset turnover and cash conversion cycle are not meaningful (no revenue, no debt, no interest expense, no inventory). FY2022 opening-cash figure for the burn ratio uses 30 June 2021 cash of A$32.716m.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | Contents | Products/services |
|---|---|---|
Research & Development (Australia) | All activities: Exenatide/Presendin IP, preclinical research (Tessara collaboration), patent prosecution, corporate administration | Presendin™ (sustained-release Exenatide) — no commercial products |
Results by Segment and Revenue by Segment (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
R&D segment operating revenue (AUD K) | 0 | 0 | 0 | 0 | 0 |
R&D segment other income (AUD K) | 262 | 1,256 | 1,704 | 462 | 192 |
R&D segment pre-tax result (AUD K) | -3,953 | -7,750 | -1,642 | -477 | -1,352 |
Contribution to group revenue (%) | 100 | 100 | 100 | 100 | 100 |
Group Entities
| Entity | Jurisdiction | Ownership FY2025 | Ownership FY2026 | Role |
|---|---|---|---|---|
Invex Therapeutics Ltd | Australia | Parent | Parent | Listed parent, IP holder |
Invex Therapeutics Ltd (UK) | United Kingdom | 100% | 0% (dissolved 24 Feb 2026) | Former employer of UK clinical team; claimant of UK R&D tax credits |
Income Statement and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating revenue (AUD K) | 0 | 0 | 0 | 0 | 0 |
Other income total (AUD K) | 262 | 1,256 | 1,704 | 462 | 192 |
Interest income (AUD K) | 80 | 797 | 492 | 232 | 128 |
R&D tax rebate income (AUD K) | 182 | 459 | 1,212 | 229 | 47 |
Other revenue (AUD K) | 0 | 0 | 0 | 0 | 17 |
Gross profit (AUD K) | 0 | 0 | 0 | 0 | 0 |
R&D expense (AUD K) | 2,963 | 7,400 | 2,039 | 204 | 520 |
Finance, compliance and admin expense (AUD K) | 900 | 1,125 | 1,170 | 718 | 1,024 |
Share-based payment expense (AUD K) | 352 | 481 | 138 | 16 | 0 |
Total operating expenses (AUD K) | 4,215 | 9,006 | 3,346 | 938 | 1,544 |
Operating income before other income (AUD K) | -4,215 | -9,006 | -3,346 | -938 | -1,544 |
EBITDA excl. interest income (AUD K) | -4,033 | -8,547 | -2,134 | -709 | -1,481 |
Pre-tax income (AUD K) | -3,953 | -7,750 | -1,642 | -477 | -1,352 |
Income tax (AUD K) | 0 | 0 | 0 | 0 | 0 |
Net income (AUD K) | -3,953 | -7,750 | -1,642 | -477 | -1,352 |
Total comprehensive income (AUD K) | -3,950 | -7,732 | -1,679 | -457 | -1,352 |
EPS basic (AUD cents) | -5.26 | -10.31 | -2.18 | -0.63 | -1.80 |
EPS diluted (AUD cents) | -5.26 | -10.31 | -2.18 | -0.63 | -1.80 |
Dividends per share (AUD cents) | 0 | 0 | 0 | 0 | 0 |
Capital return per share (AUD cents) | 0 | 0 | 18.63 | 0 | 0 |
Key Financials
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Phase III clinical trial (AUD K) | 762 | 3,847 | 1,081 | 30 | 0 |
Manufacturing (Peptron drug and placebo) (AUD K) | 326 | 744 | 0 | 0 | 0 |
Consultants (AUD K) | 715 | 1,789 | 285 | 137 | 441 |
Employee costs (AUD K) | 510 | 293 | 210 | 0 | 0 |
COO costs (AUD K) | 0 | 312 | 274 | 0 | 0 |
CSO executive director fees (AUD K) | 315 | 299 | 88 | 0 | 0 |
Patent expenses (AUD K) | 143 | 117 | 73 | 37 | 75 |
Regulatory advice and other R&D (AUD K) | 191 | 0 | 27 | 0 | 0 |
Total R&D (AUD K) | 2,963 | 7,400 | 2,039 | 204 | 520 |
Key Financials — Executive director fees
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Executive director fees (AUD K) | 139 | 180 | 340 | 172 | 94 |
Non-executive director fees (AUD K) | 160 | 160 | 150 | 60 | 131 |
Accounting and company secretarial (AUD K) | 132 | 148 | 291 | 154 | 141 |
Legal fees (AUD K) | 109 | 31 | 30 | 4 | 209 |
Audit, corporate advice and tax (AUD K) | 68 | 61 | 84 | 64 | 142 |
Insurance (AUD K) | 92 | 177 | 95 | 72 | 66 |
Investor relations and PR (AUD K) | 51 | 112 | 15 | 24 | 28 |
Travel and entertainment (AUD K) | 31 | 103 | 59 | 60 | 17 |
Transaction costs (AUD K) | 0 | 0 | 0 | 0 | 75 |
Total admin (AUD K) | 900 | 1,125 | 1,170 | 718 | 1,024 |
Balance Sheet and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Cash and cash equivalents (AUD K) | 29,339 | 22,470 | 6,025 | 5,375 | 1,516 |
Short-term term deposits (AUD K) | 0 | 0 | 0 | 0 | 2,500 |
Cash plus term deposits (AUD K) | 29,339 | 22,470 | 6,025 | 5,375 | 4,016 |
Other receivables (AUD K) | 146 | 334 | 95 | 93 | 47 |
Total assets (AUD K) | 29,485 | 22,804 | 6,120 | 5,468 | 4,064 |
Goodwill and intangibles (AUD K) | 0 | 0 | 0 | 0 | 0 |
Trade and other payables (AUD K) | 1,004 | 1,572 | 432 | 221 | 153 |
Short-term debt (AUD K) | 0 | 0 | 0 | 0 | 0 |
Long-term debt (AUD K) | 0 | 0 | 0 | 0 | 0 |
Net debt (AUD K) | -29,339 | -22,470 | -6,025 | -5,375 | -4,016 |
Total liabilities (AUD K) | 1,004 | 1,572 | 432 | 221 | 153 |
Contributed equity (AUD K) | 36,413 | 36,413 | 22,412 | 22,412 | 22,412 |
Reserves (AUD K) | 1,897 | 2,397 | 2,497 | 2,533 | 2,533 |
Accumulated losses (AUD K) | -9,829 | -17,579 | -19,221 | -19,698 | -21,035 |
Total equity (AUD K) | 28,481 | 21,231 | 5,688 | 5,247 | 3,910 |
Working capital (AUD K) | 28,481 | 21,231 | 5,688 | 5,247 | 3,910 |
Book value per share (AUD cents) | 37.90 | 28.25 | 7.57 | 6.98 | 5.20 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Payments to suppliers and employees (AUD K) | -3,639 | -8,125 | -4,148 | -1,114 | -1,535 |
R&D tax rebate received (AUD K) | 182 | 459 | 1,212 | 229 | 49 |
Interest received (AUD K) | 80 | 797 | 492 | 232 | 129 |
Operating cash flow (AUD K) | -3,377 | -6,869 | -2,444 | -653 | -1,359 |
Capex (AUD K) | 0 | 0 | 0 | 0 | 0 |
Free cash flow (AUD K) | -3,377 | -6,869 | -2,444 | -653 | -1,359 |
Investing cash flow incl. term deposits (AUD K) | 0 | 0 | 0 | 0 | -2,500 |
Capital return paid (AUD K) | 0 | 0 | -14,001 | 0 | 0 |
Dividends paid (AUD K) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (AUD K) | 0 | 0 | 0 | 0 | 0 |
Equity raised (AUD K) | 0 | 0 | 0 | 0 | 0 |
Net change in cash (AUD K) | -3,377 | -6,869 | -16,445 | -653 | -3,859 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE year-end equity basis (%) | -13.9 | -36.5 | -28.9 | -9.1 | -34.6 |
ROA year-end assets basis (%) | -13.4 | -34.0 | -26.8 | -8.7 | -33.3 |
Current ratio (x) | 29.4 | 14.5 | 14.2 | 24.8 | 26.5 |
Debt to equity (x) | 0 | 0 | 0 | 0 | 0 |
Cash per share (AUD cents) | 39.04 | 29.90 | 8.02 | 7.15 | 5.34 |
Operating cash burn as % of opening cash (%) | 10.3 | 23.4 | 10.9 | 10.8 | 25.3 |
Revenue by Region
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Australia operating revenue (AUD K) | 0 | 0 | 0 |
United Kingdom operating revenue (AUD K) | 0 | 0 | 0 |
Rest of world operating revenue (AUD K) | 0 | 0 | 0 |
UK R&D tax rebate cash received (AUD K) | 1,212 | 229 | 0 |
Share Count (millions) and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Shares on issue (millions) | 75.15 | 75.15 | 75.15 | 75.15 | 75.15 |
Book value per share (AUD cents) | 37.90 | 28.25 | 7.57 | 6.98 | 5.20 |
Cash and deposits per share (AUD cents) | 39.04 | 29.90 | 8.02 | 7.15 | 5.34 |
Dividends per share (AUD cents) | 0 | 0 | 0 | 0 | 0 |
Capital return per share (AUD cents) | 0 | 0 | 18.63 | 0 | 0 |
Share Price and Market Valuation
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Year-end share price (AUD) | 0.06 | 0.09 | 0.09 |
Year-end market cap (AUD Mn) | 4.5 | 6.8 | 6.8 |
Price to book (x) | 0.79 | 1.29 | 1.73 |
Share Price & Returns
| Reference | Price / data |
|---|---|
IPO price (Jul 2019) | A$0.40 |
Placement price (May 2020) | A$1.30 |
Capital return (Dec 2023) | A$0.1863 per share returned |
52-week range (as of early 2026, Yahoo) | A$0.059 – A$0.18 |
52-week range (Stocklight, Jul 2026) | A$0.075 – A$0.18 |
Latest verified trading (23–24 Jul 2026) | A$0.115–0.12; market cap ≈ A$8–9m |
Total shareholder return FY2024 / FY2025 (Market Index) | -70.0% / +48.4% |
Beta (5Y monthly, Yahoo) | 0.22 |
Valuation Snapshot
| Multiple | Value | Comment |
|---|---|---|
P/E | n/m | Loss-making |
EV | ≈ A$4.3m | Market cap less A$4.0m cash/deposits |
EV/EBITDA | n/m | Negative EBITDA |
EV/Sales | n/m | Nil revenue |
P/B | ≈ 2.1x | vs equity A$3.91m |
Market cap / cash | ≈ 2.1x | Market ascribes ~A$4m to IP, listing and tax attributes |
Capital Markets
| Item | Status |
|---|---|
Analyst consensus | None — not covered by major brokers (Market Index) |
Dividend policy | Directors do not propose dividends; none ever paid |
Buyback authorisation | None (no on-market buyback program) |
Credit ratings (Moody's/S&P/Fitch) | Not rated |
Debt maturity profile | No debt |
Options overhang | 1.11m options at A$0.67 expiring 1 Dec 2026 — deeply out of the money (≈1.5% of issued capital) |
Exercise price note | Options were originally struck at A$0.87 (FY2023 AR) and are shown at A$0.67 from FY2024, consistent with a capital-return adjustment of ≈A$0.19 |
Analyst Conclusions
Management guidance
None. The Board indicates continued review of investment opportunities and progression of the expanded Tessara AD program, with no likely developments disclosed beyond these.
Consensus growth expectations
None (no analyst coverage).
Bull case
-
Shell value with a floor: cash and deposits of A$4.02m (5.34c/share) against a share price around 11c means the market is paying only ~A$4m for listing status, ~900-holder register, patents, ODDs and A$2.7m of tax-effected losses — a modest premium for a transaction-ready vehicle.
-
Board built for a deal: the November 2025 board (a corporate lawyer, a former Big-4/McKinsey healthcare M&A adviser and a serial Perth small-cap chairman), installed with substantial-holder support, appears designed to execute an asset injection or reverse takeover that the prior board's Fragile X deal attempted.
-
Optionality in IP: granted US/EU use patents, the EU TBI orphan pathway and Peptron's ROFR over global IIH rights provide multiple potential monetisation routes for cash or equity.
Bear case
-
Value leakage: cash fell A$1.36m in FY2026, including over A$0.3m of contest-related legal, advisory and termination costs; without a deal, the floor erodes by ~A$1–2m per year.
-
Scientific thesis impaired: the company's own market assessment rendered Presendin uneconomic in IIH, and large GLP-1 neuro trials (Exenatide in Parkinson's, semaglutide in AD) have reported negative results, leaving in vitro ADBrain™ data with limited partnering currency.
-
No people, no alignment: no executives, nil director shareholdings, a concentrated register and a history of abrupt board turnover create execution and governance risk; any transaction will likely involve heavy dilution at prices near or below cash backing.
Catalysts and monitorables (next 12 months)
| Catalyst / monitorable | Expected timing | Why it matters |
|---|---|---|
| Q1 FY2027 Appendix 4C | By 31 Oct 2026 | Burn rate under expanded Tessara program |
| 2026 AGM | Likely Nov–Dec 2026 | Board re-election, incentive plan, any strategic resolutions |
| Expiry of 1.11m options | 1 Dec 2026 | Removes overhang |
| Tessara expanded program results | Late CY2026 – 1H CY2027 (inferred) | Determines whether AD data supports partnering |
| Announcement of acquisition, RTO or IP sale | Unscheduled | Primary value driver |
| Substantial holder notices (Tattarang, Peterson/Celtic) | Ongoing | Signals of control intentions |
| H1 FY2027 Appendix 4D | Feb 2027 | Cash position and cost discipline |
| ASX compliance posture | Ongoing | Risk of queries on adequacy of operations |
Concluding analyst verdict
Invex Therapeutics is no longer an operating drug developer in any meaningful sense; it is a lightly resourced listed vehicle holding cash, a niche IP estate and a small preclinical research option. The pivotal strategic decision — terminating the IIH EVOLVE Phase III in August 2023 — was arguably correct: the company's own market assessment showed that the weight-loss superiority and price trajectory of semaglutide-class drugs would undermine an orphan-priced, weaker-weight-loss Exenatide formulation in a disease whose primary management principle is weight reduction. Returning A$14.0m to shareholders rather than pursuing a speculative pivot was shareholder-friendly. Since then, however, the residual company has struggled to create value. Losses re-accelerated in FY2026 to A$1.35m, a third of which is attributable to a boardroom contest that also killed a potential pipeline-diversifying acquisition. The Alzheimer's program, while scientifically interesting (a ~40% reduction in neurofilament light chain and lower IL-6/IL-8 in human microtissues), is in vitro, mechanistically inconsistent on Tau and amyloid, and arrives after negative large-scale GLP-1 neurodegeneration readouts, which limits its partnering value.
The investment case therefore reduces to a transaction call. At roughly 11c per share against 5.3c of cash per share, the market prices about A$4m of option value on the new board's ability to execute an asset injection, reverse takeover or IP sale on terms that do not destroy the cash floor. The concentrated, family-office-dominated register (Tattarang 11.77%; Peterson/Celtic-associated interests) makes such a transaction feasible but also means minority holders' outcomes will be shaped by a few holders' agendas. For institutional purposes, Invex is uninvestable on fundamentals and suitable only as a special-situation shell exposure. Rating framework (analyst, not a recommendation): speculative / event-driven. Key test: whether a value-accretive transaction is announced before cash and deposits fall below roughly A$3m.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Appointed | Background |
|---|---|---|---|
Mr David Wheeler FAICD | Non-Executive Chairman | Director since 8 Nov 2023; Chairman following Nov 2025 board reconstitution | 30+ years of senior executive, directorship and corporate advisory experience; founding Director and Partner of Pathways Corporate (Perth boutique corporate advisory). Current: Chair of OZZ Resources, Avira Resources, Yugo Metals; NED of Ragnar Metals, MOAB, Cycliq Group, Earth Energy |
Mr Simon Owen | Non-Executive Director | 10 Nov 2025 | 35+ years as corporate and commercial lawyer and corporate adviser, with focus on developing businesses, innovation, IP and capital markets; prior chair/director roles in listed and unlisted companies |
Prof Warren Harding AM | Non-Executive Director | 10 Nov 2025 | 30+ years across global healthcare, biotech and medtech; former Managing Partner at Accenture, Deloitte and PwC; Senior Adviser to McKinsey & Co; Board director of the Australian Digital Health Agency; former member of WA Disability Services Commission (2020–24); co-founder/director of two emerging medtech companies |
Mr Tim Slate CA | Company Secretary | 10 Nov 2025 (joint; sole since 23 Mar 2026) | 15+ years in accounting and company secretarial roles; B.Com (UWA), Chartered Accountant, AGIA, GAICD |
Directors' Remuneration
| Name | Cash fees (AUD) | Termination benefit (AUD) | Share-based (AUD) | Total (AUD) |
|---|---|---|---|---|
David Wheeler | 47,500 | 0 | 0 | 47,500 |
Simon Owen | 39,800 | 0 | 0 | 39,800 |
Warren Harding | 30,800 | 0 | 0 | 30,800 |
David McAuliffe (to 7 Nov 2025) | 12,500 | 0 | 0 | 12,500 |
Dr Thomas Duthy (to 7 Nov 2025) | 71,665 | 22,291 | 0 | 93,956 |
Total KMP | 202,265 | 22,291 | 0 | 224,556 |
Directors' Remuneration (Annual)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total KMP remuneration (AUD K) | 1,248 | 1,747 | 1,284 | 341 | 225 |
KMP share-based payments (AUD K) | 281 | 462 | 130 | 13 | 0 |
Governance Overview
| Attribute | Status |
|---|---|
Board size | 3 (all non-executive) |
Independence | Not formally classified in the FY2026 AR; on the face of disclosures, all three are non-executive with nil shareholdings. Wheeler's Pathways Corporate advisory role and the circumstances of the November 2025 appointments (following a substantial shareholder's requisition) should be considered when assessing independence |
Chair/CEO separation | No CEO; Chair is non-executive |
Gender diversity | 0% female directors (FY2023: 40% female board representation) |
Board meetings FY2026 | 5 (Wheeler 5/5; Owen 2/2; Harding 2/2; Duthy 3/3; McAuliffe 3/3) |
Say-on-pay | 82.87% support at 2025 AGM (held 17 Feb 2026); 97.5% at 2023 AGM |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
10 Jul 2023 | Dr Jason Loveridge (Chair) and Prof Alexandra Sinclair (ED/CSO) resign | Major shareholders withdrew support after 28 Jun 2023 trial update |
8 Nov 2023 | David Wheeler appointed NED | Post-trial-closure board refresh |
1 Feb 2024 | COO Carol Parish employment terminated (A$82k redundancy) | UK team redundancies |
30 Jun 2024 | Dr Megan Baldwin retires | Board downsizing |
Sep–Oct 2025 | Celtic Capital Pte Ltd (substantial holder) requisitions meeting to remove Chair McAuliffe and ED Duthy; Board (other than Wheeler) recommended against | Governance contest; exclusivity on acquisition target ended |
7 Nov 2025 | Duthy, McAuliffe and Company Secretary/CFO Narelle Warren resign; requisitioned meeting cancelled | Contest resolved in requisitioner's favour without a vote |
10 Nov 2025 | Simon Owen and Prof Warren Harding AM appointed; Tim Slate and Carla Healy appointed joint Company Secretaries | New board installed |
23 Mar 2026 | Carla Healy resigns as joint Company Secretary | Tim Slate remains |
Major Shareholders
| Rank | Holder | Shares | % |
|---|---|---|---|
| 1 | Tattarang (Forrest family private investment group) | 8,846,154 | 11.77 |
| 2 | Peterson | 5,600,000 | 7.45 |
| 3 | Tisia Nominees Pty Ltd (Henderson Family A/C) | 3,725,000 | 4.96 |
| 4 | Mr Jason Loveridge (co-founder) | 3,374,462 | 4.49 |
| 5 | Mr David Jerimiah McAuliffe (former Chair) | 2,850,001 | 3.79 |
| 6 | JK Nominees Pty Ltd (The JK Fund A/C) | 2,750,000 | 3.66 |
| 7 | Dr Paul Francis Worth | 2,500,000 | 3.33 |
| 8 | Celtic Finance Corp Pty Ltd | 2,390,000 | 3.18 |
| 9 | Mrs Kathryn Salkilld | 2,293,000 | 3.05 |
| 10 | Porjed Pty Ltd (Deporj A/C) | 2,239,817 | 2.98 |
11–20 | Bannaby Investments, Warragoon Investments, Rock the Polo, Anthony Grist, Andrew Clayton, Zerrin Investments, Hammerhead Holdings, Chelsea Investments (WA), Okanagan Trading, De Nicola Family S/F | 11,538,518 | 15.35 |
| — | Top 20 total | 48,106,952 | 64.01 |
Competitive Landscape
Competitors by Segment
| Indication | Competitor / alternative | Type | Relative positioning |
|---|---|---|---|
IIH | Novo Nordisk — semaglutide (Ozempic/Wegovy/Rybelsus) | Approved GLP-1RA for obesity/diabetes, used off-label to drive weight loss | Decisive: the reason Invex terminated EVOLVE (superior weight loss, scale pricing) |
IIH | Eli Lilly — tirzepatide (Mounjaro/Zepbound) | Approved GIP/GLP-1 agonist | Further raises the bar for weight-loss-driven IIH management |
IIH | Generic acetazolamide and topiramate | Off-label standard of care | Cheap incumbents; no approved IIH-specific therapy per Invex disclosures |
IIH | Bariatric surgery, CSF shunting, venous sinus stenting, optic nerve sheath fenestration | Surgical/device | Established for refractory cases |
IIH | AstraZeneca / University of Birmingham — 11β-HSD1 inhibitor (AZD4017) research | Investigational | — |
TBI / raised ICP | Hyperosmolar therapy (mannitol, hypertonic saline), decompressive craniectomy, CSF drainage | Standard of care | No EMA/FDA-approved drug specifically for intracranial hypertension in TBI per Invex |
Alzheimer's disease | Eli Lilly — donanemab (Kisunla); Eisai/Biogen — lecanemab (Leqembi) | Approved anti-amyloid antibodies | Dominant disease-modifying class |
Alzheimer's disease | Novo Nordisk — semaglutide (evoke program) | GLP-1RA in AD | Large-pharma GLP-1 AD test; reported negative (see 13.3) |
Alzheimer's (ASX peers) | Actinogen Medical (ASX: ACW), Alterity Therapeutics (ASX: ATH), Neurotech International (ASX: NTI) | ASX-listed CNS biotechs | Clinical-stage peers competing for the same small-cap investor capital |
Exenatide supply | AstraZeneca (Byetta/Bydureon originator) | Originator of Exenatide | Controls the reference product; generic/biosimilar context relevant to pricing |
Peer Comparison FY2026
| Attribute | Invex (FY2026) | Novo Nordisk | Eli Lilly | ASX CNS micro/small-cap peers |
|---|---|---|---|---|
Operating revenue | Nil | Tens of billions (USD equivalent) | Tens of billions (USD) | Generally nil/minimal |
Development stage | Preclinical | Commercial | Commercial | Phase 1–3 |
R&D spend | A$0.52m | Billions | Billions | Several A$m to tens of A$m |
Revenue growth | n/m | Not compiled here | Not compiled here | Not compiled here |
Margins | n/m | Not compiled here | Not compiled here | n/m |
Recent Developments
There have been no product launches, contract wins, guidance revisions, layoffs (no staff), or regulatory actions in the period.



